KineMed’s stable isotope technology is a translational and personalized medicine platform to identify and characterize novel biomarkers in cerebrospinal fluid to facilitate development of new drugs for the treatment of Alzheimer’s disease for Bristol-Myers Squibb.
Francis Cuss, MD and Senior Vice President of discovery and exploratory clinical research at Bristol-Myers Squibb, said: “KineMed has a unique approach to identifying biomarkers for neurodegenerative diseases. We value KineMed’s expertise in this area and look forward to working together in the fight against neurodegenerative diseases.”
Robert B. Stein, CEO of KineMed, said: “we are very enthusiastic about working with Bristol-Myers Squibb as we believe our expertise and platform are most powerful when applied in the context of important drug R&D programs.”